Natera Inc Stock
Price
Target price
€144.00
€144.00
-0.690%
-1.0
-0.690%
-
29.08.25 / Tradegate
WKN: A14VPJ / Name: Natera / Stock / Healthcare Equipment & Supplies / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Natera Inc Stock
Natera Inc shows a slight decrease today, losing -€1.000 (-0.690%) compared to yesterday.
Pros and Cons of Natera Inc in the next few years
Pros
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Natera Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Natera Inc | -0.690% | 1.408% | 22.034% | 34.579% | -5.263% | 198.755% | - |
| SI-BONE Inc | 0.000% | 1.439% | -7.843% | -4.082% | 8.462% | - | - |
| Orasure Tech | -5.920% | 16.260% | -0.694% | -26.289% | -16.374% | -28.141% | -70.515% |
| scPharmaceuticals | -0.680% | 20.000% | 1.088% | 6.027% | 43.333% | -18.526% | -30.165% |
News
Natera (NTRA) Q2 Revenue Jumps 32%
Natera (NASDAQ:NTRA), a leader in genetic testing across oncology, women's health, and organ health, reported its earnings for Q2 2025 on August 7, 2025. The most significant news was a 32.2%
Natera Stock: Insider Sales Cast Shadow on Growth
Natera's stock has rewarded investors with an impressive 60% gain over the past twelve months, but recent insider transactions have raised eyebrows despite strong operational performance. On April
27.5% of Stanley Druckenmiller's $3.7 Billion Portfolio Is Invested in These 3 Under-the-Radar AI Stocks
Stanley Druckenmiller is in an elite league of investors that includes the likes of Warren Buffett. He ran his hedge fund firm, Duquesne Capital Management, for 30 years, posting eye-popping average